Identification
Name2-phospho-D-glyceric acid
Accession NumberDB01709  (EXPT00143, EXPT02490, DB03465)
TypeSmall Molecule
GroupsExperimental
Description

A 2-phosphoglyceric acid in which the glyceric acid moiety has D (R) configuration.

Structure
Thumb
Synonyms
2-phospho-D-glycerate
D-glycerate 2-phosphate
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIINot Available
CAS numberNot Available
WeightAverage: 186.0572
Monoisotopic: 185.99293909
Chemical FormulaC3H7O7P
InChI KeyGXIURPTVHJPJLF-UWTATZPHSA-N
InChI
InChI=1S/C3H7O7P/c4-1-2(3(5)6)10-11(7,8)9/h2,4H,1H2,(H,5,6)(H2,7,8,9)/t2-/m1/s1
IUPAC Name
(2R)-3-hydroxy-2-(phosphonooxy)propanoic acid
SMILES
OC[C@@H](OP(O)(O)=O)C(O)=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
2-dehydro-3-deoxyphosphooctonate aldolaseProteinunknownNot AvailableAquifex aeolicus (strain VF5)O66496 details
2,3-bisphosphoglycerate-independent phosphoglycerate mutaseProteinunknownNot AvailableGeobacillus stearothermophilusQ9X519 details
Triosephosphate isomeraseProteinunknownNot AvailablePlasmodium falciparumQ07412 details
Beta-enolaseProteinunknownNot AvailableHumanP13929 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Warburg EffectMetabolicSMP00654
Fructose-1,6-diphosphatase deficiencyDiseaseSMP00562
Fanconi-bickel syndromeDiseaseSMP00572
GlycolysisMetabolicSMP00040
Glycogenosis, Type IA. Von gierke diseaseDiseaseSMP00581
Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke DiseaseDiseaseSMP00374
Phosphoenolpyruvate carboxykinase deficiency 1 (PEPCK1)DiseaseSMP00560
Triosephosphate isomeraseDiseaseSMP00563
GluconeogenesisMetabolicSMP00128
Glycogenosis, Type VII. Tarui diseaseDiseaseSMP00531
Glycogenosis, Type IBDiseaseSMP00573
Glycogenosis, Type ICDiseaseSMP00574
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility20.3 mg/mLALOGPS
logP-2.2ALOGPS
logP-1.6ChemAxon
logS-0.96ALOGPS
pKa (Strongest Acidic)0.81ChemAxon
pKa (Strongest Basic)-3.1ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area124.29 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity31.26 m3·mol-1ChemAxon
Polarizability13.36 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9403
Blood Brain Barrier+0.9382
Caco-2 permeable-0.7554
P-glycoprotein substrateNon-substrate0.7893
P-glycoprotein inhibitor INon-inhibitor0.9051
P-glycoprotein inhibitor IINon-inhibitor0.9223
Renal organic cation transporterNon-inhibitor0.933
CYP450 2C9 substrateNon-substrate0.8132
CYP450 2D6 substrateNon-substrate0.8497
CYP450 3A4 substrateNon-substrate0.6523
CYP450 1A2 substrateNon-inhibitor0.9177
CYP450 2C9 inhibitorNon-inhibitor0.8961
CYP450 2D6 inhibitorNon-inhibitor0.9223
CYP450 2C19 inhibitorNon-inhibitor0.8942
CYP450 3A4 inhibitorNon-inhibitor0.9474
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9754
Ames testNon AMES toxic0.8232
CarcinogenicityNon-carcinogens0.704
BiodegradationReady biodegradable0.8083
Rat acute toxicity2.0931 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9726
hERG inhibition (predictor II)Non-inhibitor0.9122
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MS (4 TMS)splash10-014j-1986100000-67b36247ae0c01d6630fView in MoNA
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-000i-0900000000-80caf2498862e856c8fcView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-004i-9100000000-1518e606c03a8697d1b9View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-004i-9000000000-66ec419add3cb3e1fd32View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-004i-9000000000-b7f464912df9166dc597View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-004i-9000000000-d09faea5291df7a04b70View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , positivesplash10-0udr-0900000000-09027263f64d0e1059c6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , positivesplash10-0udi-1900000000-8eeb1d2a8432d1e44448View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , positivesplash10-0f6t-8900000000-3b714e664b948f61ac7eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , positivesplash10-0023-9000000000-ed83591fbfd15323cd6dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , positivesplash10-001m-9000000000-39cdf9729f381069e45fView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-000j-9300000000-24ac9683b32428f58197View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0002-9600000000-b12281d6d89eef904e6bView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0007-9000000000-a07c4a51c820b32ec8bdView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-001i-4900000000-516a86a1a17689399892View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-004i-9500000000-b33f3e08e2e8b3d5aed5View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-004i-9000000000-07016cc3ecca7d5e323bView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as sugar acids and derivatives. These are compounds containing a saccharide unit which bears a carboxylic acid group.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganic oxygen compounds
Sub ClassOrganooxygen compounds
Direct ParentSugar acids and derivatives
Alternative ParentsMonoalkyl phosphates / Beta hydroxy acids and derivatives / Monosaccharides / Monocarboxylic acids and derivatives / Carboxylic acids / Primary alcohols / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
SubstituentsBeta-hydroxy acid / Glyceric_acid / Monoalkyl phosphate / Hydroxy acid / Monosaccharide / Organic phosphoric acid derivative / Phosphoric acid ester / Alkyl phosphate / Monocarboxylic acid or derivatives / Carboxylic acid
Molecular FrameworkAliphatic acyclic compounds
External Descriptors2-phosphoglyceric acid (CHEBI:17835 )

Targets

Kind
Protein
Organism
Aquifex aeolicus (strain VF5)
Pharmacological action
unknown
General Function:
3-deoxy-8-phosphooctulonate synthase activity
Specific Function:
Not Available
Gene Name:
kdsA
Uniprot ID:
O66496
Molecular Weight:
29734.17 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Geobacillus stearothermophilus
Pharmacological action
unknown
General Function:
Manganese ion binding
Specific Function:
Essential for rapid growth and for sporulation. Catalyzes the interconversion of 2-phosphoglycerate (2-PGA) and 3-phosphoglycerate (3-PGA).
Gene Name:
gpmI
Uniprot ID:
Q9X519
Molecular Weight:
57002.48 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Plasmodium falciparum
Pharmacological action
unknown
General Function:
Triose-phosphate isomerase activity
Specific Function:
Not Available
Gene Name:
TPI
Uniprot ID:
Q07412
Molecular Weight:
27934.505 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phosphopyruvate hydratase activity
Specific Function:
Appears to have a function in striated muscle development and regeneration.
Gene Name:
ENO3
Uniprot ID:
P13929
Molecular Weight:
46986.485 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 17:01